Diabetes and obesity - Issue 1/2024
Reviews
13
Integration of glycemic compensation markers, including glycemic variability in patients with diabetes mellitus
Oliver Viktor Rácz, Eva Lovásová, Jaroslava Nováková, Adriana Phillipiová
25
Inklisiran and its role in lipid-lowering therapy
Olga Bobelová
36
Type 2 diabetes mellitus and obesity – dangerous companions
Zbynek Schroner
41
53
62
Long-term sustainability of metabolic compensation in telemedicine use – results of 18 months follow-up
Jozef Lacka, Pavol Košík, Klaudia Mesíková
70
Diabetic distress from clinical diabetology view
Daniel Kolény, Marcela Murínová
Diabetes and obesity
2024 Issue 1
Most read in this issue
- Early use of SGLT2-inhibitors i in the treatment of type 2 diabetes mellitus
- Current position of GLP-1 receptor agonists in type 2 diabetes mellitus treatment
- Coexistence of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of a patient with type 2 diabetes mellitus
- Type 2 diabetes mellitus and obesity – dangerous companions